Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Professor David Nutt discusses Awakn's PTSD therapeutics collaboration with Graft Polymer UK
MP3•Episode home
Manage episode 430353370 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Awakn Life Sciences chief scientific officer Professor David Nutt speaks with Proactive's Stephen Gunnion about the company's new commercial collaboration with Graft Polymer UK. This partnership aims to advance Awakn's novel aminoindane new chemical entity (NCE) series, targeting trauma disorders such as PTSD, depression, and addictions. In the interview, Nutt highlighted the serious nature of PTSD, describing it as a "disorder of this century." He noted that current treatments are inadequate, and the collaboration seeks to enhance the bioavailability and pharmacokinetics of these new therapeutics. The partnership also includes a £300,000 investment from Graft Polymer UK to improve drug delivery systems. Nutt explained that the new technology could make treatment more efficient, reducing the time needed for therapeutic sessions, and improving patient outcomes. He emphasised the importance of finding better solutions for trauma-related disorders, particularly given the increasing prevalence of PTSD among populations affected by war and other traumatic events. To hear more about how Awakn Life Sciences and Graft Polymer UK are working together to revolutionise PTSD treatment, watch the full interview with Professor David Nutt. For more videos, visit Proactive's YouTube channel. Don’t forget to give the video a like, subscribe to the channel, and enable notifications for future content. #AwaknLifeSciences #PTSDTreatment #MentalHealth #DavidNutt #PharmaceuticalInnovation #GraftPolymer #TraumaTherapy #MentalHealthRevolution #NewDrugDevelopment #Bioavailability #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
607 episodes
MP3•Episode home
Manage episode 430353370 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Awakn Life Sciences chief scientific officer Professor David Nutt speaks with Proactive's Stephen Gunnion about the company's new commercial collaboration with Graft Polymer UK. This partnership aims to advance Awakn's novel aminoindane new chemical entity (NCE) series, targeting trauma disorders such as PTSD, depression, and addictions. In the interview, Nutt highlighted the serious nature of PTSD, describing it as a "disorder of this century." He noted that current treatments are inadequate, and the collaboration seeks to enhance the bioavailability and pharmacokinetics of these new therapeutics. The partnership also includes a £300,000 investment from Graft Polymer UK to improve drug delivery systems. Nutt explained that the new technology could make treatment more efficient, reducing the time needed for therapeutic sessions, and improving patient outcomes. He emphasised the importance of finding better solutions for trauma-related disorders, particularly given the increasing prevalence of PTSD among populations affected by war and other traumatic events. To hear more about how Awakn Life Sciences and Graft Polymer UK are working together to revolutionise PTSD treatment, watch the full interview with Professor David Nutt. For more videos, visit Proactive's YouTube channel. Don’t forget to give the video a like, subscribe to the channel, and enable notifications for future content. #AwaknLifeSciences #PTSDTreatment #MentalHealth #DavidNutt #PharmaceuticalInnovation #GraftPolymer #TraumaTherapy #MentalHealthRevolution #NewDrugDevelopment #Bioavailability #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
607 episodes
すべてのエピソード
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.